Over 200 companies advancing 220+ glioblastoma drugs in clinical trials, signaling progress in brain cancer treatment.

More than 200 companies are actively developing over 220 drugs for glioblastoma, the most aggressive brain cancer, with 16+ drugs in late-stage trials. Key therapies include targeted treatments, immunotherapies, and metabolic modulators, reflecting a shift from traditional chemotherapy. Notable drugs like Paxalisib and BPM31510 show promise, while recent clinical collaborations and regulatory progress highlight growing momentum in the field. This expansion offers hope for improved treatment options despite glioblastoma's complexity and poor prognosis.